TABLE 2.
Antifungal and HEPB susceptibilities of C. albicans ATCC 10231 (MIC, μg/ml ± standard deviation) after 24-h exposure to 0.1% HEPB (wt/vol, n = 3)
| Treatmenta | HEPB | AND | AB | MF | CAS | FC | PZ | VOR | IZ | FZ |
|---|---|---|---|---|---|---|---|---|---|---|
| −HEPB | 5 mg/ml ± 0.00 | 0.10 ± 0.03 | 0.50 ± 0.00 | 0.015 ± 0.00 | 0.06 ± 0.00 | 0.12 ± 0.00 | 0.06 ± 0.00 | 0.06 ± 0.00 | 0.25 ± 0.00 | 2.00 ± 0.00 |
| +HEPB | 5 mg/ml ± 0.00 | 0.10 ± 0.03 | 0.50 ± 0.03 | 0.015 ± 0.00 | 0.06 ± 0.00 | 0.25 ± 0.00 | 0.06 ± 0.00 | 0.06 ± 0.00 | 0.25 ± 0.00 | 2.00 ± 0.00 |
a
Treatment: −HEPB, no addition of HEPB; +HEPB, addition of 0.1% HEPB (wt/vol); HEPB, ethylzingerone; AND, anidulafungin; AB, amphotericin B; MF, micafungin; CAS, caspofungin; FC, 5-flucytosine; PZ, posaconazole; VOR, voriconazole; IZ, itraconazole; FZ, fluconazole.